Scholarlink

<p>The optimal reduced-intensity conditioning (RIC) regimen for haploidentical hematopoietic stem cells transplantation (haplo-HSCT) using post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis has yet to be determined. Potential RIC regimen for haplo-HSCT in myeloid malignancies include Clofarabine-Baltimore (CloB) and TBF (thiotepa-busulfan-fludarabine). This multicenter retrospective study compared 297 adult patients receiving CloB (<i>n</i> = 59) or TBF (<i>n</i> = 238). The main diagnoses were acute myeloid leukemia (63%), 36% having adverse risk features. Median follow-up was 22.7 months. No significant differences were observed in overall (OS), progression-free (PFS), or GVHD-free relapse-free survival. However, 2-year non-relapse mortality (NRM) was higher after TBF (34% vs 21%, HR: 0.38; 95%CI: 0.20–0.75, <i>p</i> = 0.005), although the relapse incidence was lower (13% vs 23%, HR: 1.94; 95%CI: 0.98–3.87, <i>p</i> = 0.059). A 1:1 propensity score matching allowed the comparison of 53 CloB with 53 TBF. CloB was associated with improved 2-year OS (63% vs 44%, <i>p</i> = 0.02) due to a higher 2-year NRM in the TBF group (48% vs 19%, <i>p</i> = 0.002). By multivariate analysis, CloB remained associated with better OS (HR 0.52, 95% I 0.28–0.99, <i>p</i> = 0.045) and TBF with higher NRM (HR 3.43, 95%CI 1.59–7.41, <i>p</i> = 0.002). These results suggest that CloB is superior to TBF as a RIC regimen prior to haplo-HSCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC

  • 期刊论文

  • 发表日期：

    2025年9月15日

查看全文
  • Maxime Jullien,
  • Eolia Brissot,
  • Etienne Daguindau,
  • Michael Loschi,
  • Ali Bazarbachi,
  • Hélène Labussiere-Wallet,
  • Anne Huynh,
  • Aline Schmidt-Tanguy,
  • Amandine Charbonnier,
  • Pascal Turlure,
  • Florence Beckerich,
  • Raynier Devillier,
  • Jacques Olivier Bay,
  • Micha Srour,
  • Patrice Ceballos,
  • Mustafa Alani,
  • Laetitia Souchet,
  • Tony Marchand,
  • Marie-Thérèse Rubio,
  • Edouard Forcade,
  • Jérôme Cornillon,
  • Sylvain Chantepie,
  • Claude-Eric Bulabois,
  • Alban Villate,
  • Alice Garnier,
  • Pierre Peterlin,
  • Amandine Le Bourgeois,
  • Thierry Guillaume,
  • Patrice Chevallier,
  • Amandine Le Bourgeois

摘要

The optimal reduced-intensity conditioning (RIC) regimen for haploidentical hematopoietic stem cells transplantation (haplo-HSCT) using post-transplant cyclophosphamide as graft-versus-host disease (GVHD) prophylaxis has yet to be determined. Potential RIC regimen for haplo-HSCT in myeloid malignancies include Clofarabine-Baltimore (CloB) and TBF (thiotepa-busulfan-fludarabine). This multicenter retrospective study compared 297 adult patients receiving CloB (n = 59) or TBF (n = 238). The main diagnoses were acute myeloid leukemia (63%), 36% having adverse risk features. Median follow-up was 22.7 months. No significant differences were observed in overall (OS), progression-free (PFS), or GVHD-free relapse-free survival. However, 2-year non-relapse mortality (NRM) was higher after TBF (34% vs 21%, HR: 0.38; 95%CI: 0.20–0.75, p = 0.005), although the relapse incidence was lower (13% vs 23%, HR: 1.94; 95%CI: 0.98–3.87, p = 0.059). A 1:1 propensity score matching allowed the comparison of 53 CloB with 53 TBF. CloB was associated with improved 2-year OS (63% vs 44%, p = 0.02) due to a higher 2-year NRM in the TBF group (48% vs 19%, p = 0.002). By multivariate analysis, CloB remained associated with better OS (HR 0.52, 95% I 0.28–0.99, p = 0.045) and TBF with higher NRM (HR 3.43, 95%CI 1.59–7.41, p = 0.002). These results suggest that CloB is superior to TBF as a RIC regimen prior to haplo-HSCT.